公开(公告)号：US20190212325A1

公开(公告)日：2019-07-11

申请号：US15773400

申请日：2016-11-04

申请人： VIVIA BIOTECH, S.L

发明人： Juan Antonio BALLESTEROS NOBELL ,  Teresa BENNETT ,  Daniel PRIMO RAMOS ,  Paolo PROSPERO GHIA ,  Ana Belén ESPINOSA OQUILLAS ,  Julián GORROCHATEGUI GUILLÉN ,  Alicia ROBLES MATEOS ,  Pilar HERNÁNDEZ CAMPO

IPC分类号： G01N33/50 ,  C12N5/09

CPC分类号： G01N33/5011 ,  C12N5/0694 ,  C12N2500/40 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2313 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2502/30 ,  C12N2503/02 ,  C12N2513/00 ,  G01N33/5044 ,  G01N33/5088

摘要： The invention presented here relates to a method for producing an artificial environment of primary cell populations, particularly an artificial tumor environment of primary tumor cell populations and its use in an ex vivo method to test the cellular responsiveness of primary tumor cell populations to a drug or drugs. The method of the invention comprises incubation of the primary tumor cells with the artificial tumor environment and the drug or drugs and analyze the response of the primary tumor cell populations. The incubation of the primary tumor cells with the artificial tumor environment, enhances the viability of said tumor cells and/or induces greater levels of tumor cell proliferation and, consequently, increases the sensitivity and accuracy of the test with regard to the drug/s assayed.

公开(公告)号：US20190218515A1

公开(公告)日：2019-07-18

申请号：US16093867

申请日：2017-04-12

申请人： VIVIA BIOTECH, S.L.

发明人： Juan Antonio BALLESTEROS NOBELL ,  Teresa Ann BENNET ,  Pilar HERNÁNDEZ CAMPO ,  Cristina GÓMEZ GONZÁLEZ ,  Julián GORROCHATEGUI GUILLÉN ,  Joaquín MARTÍNEZ LÓPEZ ,  Alicia ROBLES MATEOS ,  Daniel PRIMOS RAMOS

IPC分类号： C12N5/0783 ,  A61P35/02 ,  A61K45/00

CPC分类号： C12N5/0638 ,  A61K39/0011 ,  A61K45/05 ,  A61K2039/5158 ,  A61K2039/572 ,  A61P35/02

摘要： Generation and identification of highly effective immune effector cell in terms of target cell-killing activity can be enhanced by optimizing the proximity between a target cell and the immune effector cell. The cancer-killing T cells described herein can provide highly effective therapies for diverse cancer types, e.g., solid cancers, hematological cancers, and metastatic forms thereof. Provided herein are ex-vivo methods of generating cancer-killing T cells, compositions comprising such immune cells; methods of using the cells, methods of selecting optimal agents for enhancing the target cell killing activity, methods of selecting an optimized immune cell and methods of using this approach to evaluate patient responsiveness to other cancer therapies.